Kairos Pharma (NYSEAMERICAN:KAPA) Shares Up 1% – What’s Next?

Shares of Kairos Pharma, LTD. (NYSEAMERICAN:KAPA) shot up 1% on Friday . The company traded as high as $0.63 and last traded at $0.62. 94,992 shares were traded during mid-day trading, a decline of 94% from the average session volume of 1,593,450 shares. The stock had previously closed at $0.62.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Maxim Group started coverage on shares of Kairos Pharma in a research note on Thursday, March 27th. They issued a “buy” rating and a $4.00 target price for the company. D. Boral Capital restated a “buy” rating and set a $9.00 price target on shares of Kairos Pharma in a report on Thursday, April 17th. Finally, HC Wainwright began coverage on shares of Kairos Pharma in a research note on Thursday, April 3rd. They issued a “buy” rating and a $12.00 price objective for the company.

Kairos Pharma Price Performance

The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.29.

Institutional Investors Weigh In On Kairos Pharma

An institutional investor recently bought a new position in Kairos Pharma stock. Armistice Capital LLC purchased a new stake in Kairos Pharma, LTD. (NYSEAMERICAN:KAPA) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,404,000 shares of the company’s stock, valued at approximately $1,314,000. Armistice Capital LLC owned approximately 10.25% of Kairos Pharma as of its most recent filing with the Securities & Exchange Commission.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.